N
Google TrendANNA BONDAR (200+) — October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:anna bondar200+natanael cano100+green card500+power outage near me10000+india2000+sony playstation1000+loki100+hubert hurkacz200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Improved survival in mult" (30 stories)

Top Headline Story

Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
Lead StoryThe ASCO Postgeneral
Aug 10

Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMkpRZGdfejRsYUNBXzE0a2VYdlZuaDBBN2l1NHZxODF4U3ZwWWZ0RFhXNHlUVUpoVFh5QTV4TWdpM25IOXB0Sk43TUJXX1JOVHJuVGtOY2Vram1aX01MbHJsazVvTFplVXhCUExVRWh4QWxNcmlZLWpFWDZ6YnRnRVp3cVJSUUw2Rk5IYkxfVWVkd1VIeWZrRjVPWW5TbEFFU0JQMG0zSm5NOGtPUjNOejYzeDZlSmhwbkVleWZFbzNnQkd6dkZZdElwTFpRbm5VUVE?oc=5" target="_blank">Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+21m ago

anna bondar

October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market

Filter stories
100+21m ago

natanael cano

Padres de Natanael Cano rompen el silencio tras retiro del cantante: "Es por el bien de nuestro hijo"

Filter stories
500+31m ago

green card

Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows

Filter stories
10000+31m ago

power outage near me

LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east

Filter stories

Search Results for "Improved survival in mult"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Teclistamab (Tecvayli) Improves Survival in Relapsed Multiple Myeloma
Oncology News Centralgeneral

Teclistamab (Tecvayli) Improves Survival in Relapsed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPZTdDYTdDNUpRbE9wZ1pwbGwxT1lhNDdBQXpQOWJsUzhSM25paGVmNzQ0LWpoQmZMbWVpWFVzcWo0VFo5dVpSNlZpRDVWLVFwcGt6eTBfMFFVdGxqdHRHZmFyTzBldGM0b183QTEwLW14LWVmc1hSMEo3ZjVfVzlMWFNQV0sxR2RuZXUtb1A1ai1fbHRQdTdXeGhkcXhWQjVOeVRTcmpBbGpfV2VsSmE3UEZDUGJiT21RTW5nUG1qOE4wdWkxeWJHMlpHeXA?oc=5" target="_blank">Teclistamab (Tecvayli) Improves Survival in Relapsed Multiple Myeloma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy
Mayo Clinic News Networktech

Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQ2JvS0duQUd5eW1lWGIyay1JZ2JocVY4OWQ3bFFubnNOT0V3Tk9TVTZlRUdrd3JvYThiWHk0UXJFWWRMLVdkM1JMUEdNNnBXMFN2LTVFV3JkdUdHNnBnbk5oRnhVcFpLVW5XdTA4eUE2ZF96NHZER1IySjA5MDgxb3R4NGFCVE1OdmVJVXltTEZObVlZN0tza1BFU1h6dTJEbERHSFlCZEZOQV9POG5HV19FQTBNWW9tdXdQVWpmRXRTWS1aVVFERURqWndRWG9qRHp6N0g4dVRxMWRCR2xLZHhiTVhsVGc3MjVVZ2RHNA?oc=5" target="_blank">Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy</a>  <font color="#6f6f6f">Mayo Clinic News Network</font>

Read Full StoryMore like this
Talquetamab-Based Regimens Improve Survival in Relapsed/Refractory Multiple Myeloma
Cancer Therapy Advisorgeneral

Talquetamab-Based Regimens Improve Survival in Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNZWZwcGk4dDBoV2NpN2Z4b05NRHNXbHdUbFl1UnByS2VWLXo4UUw2NV9ONHB1QVNQT3FrNS15SjBSQjJRYjZuRnNvdXprSzMwREtwdzBacTV3Tnp2S3RPemwxUGRDMWhNeVlUNVpuWVJoVnJPeGJRY3dhYkdfTTVQSTYxcFBtVnhCQURMMjBtNDNBODV4Vlp6NVFsOWl1YTVma1VhUng3RTRha08xNmc4aVJkWGRxRmxpQkE?oc=5" target="_blank">Talquetamab-Based Regimens Improve Survival in Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
AJMCgeneral

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNUllYTndobnpGd3JhSFMyQ1RvTnFtYlNFcHYwekcwd1IzQzdWSFc1MVJsLVFLLVVsU1ZiSGRKOThVeFhobnVjeFBOVG1maEtlZzhEOE9yWlpKdl9pbWVhdFJsZm9HVHNwZGpFOEd5cmNmcmVhcGh3cVpkZm9TVXRFeGlFTUZJT1QwTm45ODk1aVVNWk1WemdMVDBGLUlBR0l1Z1dJR2taaUFlenp2RWcycnJ3?oc=5" target="_blank">Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Multiple Myeloma Death Rates Decline as Targeted Therapies Transform Survival
Cure Todaygeneral

Multiple Myeloma Death Rates Decline as Targeted Therapies Transform Survival

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPQkhfSTU0WmVMLWwxRFVSbDZVSW45RVpLYXdzWURoc3djZW1GNVRJQkpDRld0c3dmdThxUG0tbkNCTGsxSEZuT2txUU9uYkszV0VIRmcwM245Ny1GbXoyQXB1NVJFZ2dtV0c3N3VTU2ZORDNaaWp5T0lfNVgzZUpWSG45QmFWQW9kcFFNT2l0bmFVeVdYQ2VqWHpCUGM0OXVqaTBFSlhUNFRWWFEy?oc=5" target="_blank">Multiple Myeloma Death Rates Decline as Targeted Therapies Transform Survival</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Combo treatment delays multiple myeloma progression and may improve survival, study finds
Medical Xpressgeneral

Combo treatment delays multiple myeloma progression and may improve survival, study finds

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPLXc5dWw0ZG5fTlF2dUVkYi0tdWUtc0cxXzlEbUgyckdETkRJWW5nTEY5Wlh5QS1CRkNoM3Q5cjgzRklvRHNfa2hIajVXUkxnVmdpd0xFdUZtbThKYmZJdm5WWk03M0NQSXBHZWVFRkdSWTJvZlBKZDFmdHM4T1ZiM2dUU2xBZm5sZUVN?oc=5" target="_blank">Combo treatment delays multiple myeloma progression and may improve survival, study finds</a>  <font color="#6f6f6f">Medical Xpress</font>

Read Full StoryMore like this
New treatment combination delays multiple myeloma progression and may improve survival, study finds
EurekAlert! Science News Releasesgeneral

New treatment combination delays multiple myeloma progression and may improve survival, study finds

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1PYWE2NTdZRjFGT19LQ09vWk8xMTZ6TjFnTVNabTdMX1J3bW9LeXZTVGNhWFFTYW9fb2Rha1dVakxtMGdTejRkM0lhTGFKMmljN2VtWjJIQzFKNkcz?oc=5" target="_blank">New treatment combination delays multiple myeloma progression and may improve survival, study finds</a>  <font color="#6f6f6f">EurekAlert! Science News Releases</font>

Read Full StoryMore like this
Elranatamab Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial
Oncology Nursing Newsgeneral

Elranatamab Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQMmxkNmNCeDZCVmpZRjh6a3NUcG52RWEwanExUF9fSm1jNmNTSUhzbElVNWhkRkhYTUUxMHBVWTY1blF1d0EtYWpHTUdvTG9ydEpMcUs0TlExdDh4M3pQaHNxSGRxZHd1QTdmOFpKbG05UEZ4QW5MY3pBelZNQnBkZkN2TWhjS0U1TEcwWEM1aWVjSzkwWlFHMTNkdXNocE95dUlVOXNHUUdPLWtvaGF3Ty05TQ?oc=5" target="_blank">Elranatamab Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies
ASCO Daily Newsgeneral

GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxObVQxXzZkdWM4TDJVZkFyVFNvbUhtQ1ZOUUQ1RHVFcTgwd014RFIzNHo3OEV3bzI2dENxY1Y2M1c2Skx3amJ0VDNxNEp2UlR0NmM3S3JsMVE5cXJ3SmREWC1mWmsxajhURjhEYjlxRE5MSnlKUzd0SDJlZHBZOGhSV2NqVHJLV1lyR0R4ejVYSy0tZkJ2SXZiSjRfX0Z2a1hQc3puempOdjYzd2l2dUtLOHpjOA?oc=5" target="_blank">GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Multiple Myeloma ICU Survival Improves Over Time
European Medical Journalgeneral

Multiple Myeloma ICU Survival Improves Over Time

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQZjdtSzlZaEVBTnY2eUV3X3hyWWRQM21NOS1wU1NKNWdNc0k2OFMxWnZudDJ3RUJWUklxa0k2cFdwU0o3UW1mUS02U2hrMWxYOFB4ZkF6cXdTZkRHWFRIMkJOMjVHSzFiS3Zqdk1hSkRBbEtITFNKYWppZ2ozemxHOENGWkxxSWRiWXBkRkY5Z0NnR3E5?oc=5" target="_blank">Multiple Myeloma ICU Survival Improves Over Time</a>  <font color="#6f6f6f">European Medical Journal</font>

Read Full StoryMore like this
Elranatamab Improves Survival in Phase 3 Trial for Relapsed/Refractory Multiple Myeloma
Applied Clinical Trialsgeneral

Elranatamab Improves Survival in Phase 3 Trial for Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOcDQ2dWU1T19vYnlUd0dXemwyTlNtT0VUWHNuVmh6b3VoWTZFSGpucEFZcGd6ZWZrbEVxclBOaG1sYV9jaWZVQXhXbGNLV2JEd0ZiLVp0SV9yamxIWklldlR0Yzc4ZFFLV3BpejZOaVBQc3JMUlJXelpsdWV6NXBoRGpZVmdxTzNPbkZ0ZDVBYWxOU01iUGp4M3dnOE9UMUNlZzJSVE5heVJKZw?oc=5" target="_blank">Elranatamab Improves Survival in Phase 3 Trial for Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
Natureworld

Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE83MjZyYzJZbG9FWjNUeGwwUEE5ZjItRnFadEN0Mk13Z2tLQzg1ZGxmWk9aVzdLUzdwU2hZTjNwTk95NkkwYWtOZl81YmpWLS1LUEptLTBEOXl0emdjOXVR?oc=5" target="_blank">Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Talquetamab Regimens Boost Survival in Multiple Myeloma
MedPage Todaygeneral

Talquetamab Regimens Boost Survival in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1DSVZjS2JTcVA1US1vM0NEY1JDR3phYXVxZ2FQcUppbEpyc3p5UkpzeVdRZUw0NU5nbHpzWjJYemNYWUQ0UGF3bzNGTHNPNmpVbkNRbHBLQ0VuajcwZ3JMdXlWc2Jpdw?oc=5" target="_blank">Talquetamab Regimens Boost Survival in Multiple Myeloma</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
Multiple Myeloma: Improved Prognosis With the Latest Treatments
Memorial Sloan Kettering Cancer Centergeneral

Multiple Myeloma: Improved Prognosis With the Latest Treatments

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQdG9MbGhQYlhFZ1Q1VGhtUE5Sc2YyaEtZREJ2YzdIWG4yS2pHcEN4M1kta1FUd2lPTUhCeUVueUZrM083YXNvQ0w3ZFN5bU1OQ3JOM19JbWlfMndEa0lhNERhNXhjTHk0LXB2WFJKSHpQUEV3MjJLM2xfWG5CMlNBTTBYUUlJNVE?oc=5" target="_blank">Multiple Myeloma: Improved Prognosis With the Latest Treatments</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Business Wiregeneral

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxOcVRocmc3SEdIdG5CWTlXc2hvcVYzRXZsUmlQbEtTcHJyOGhHX012NW5MSldBT0xVdW10SnZzZDJOS1ZOM29XSUhFVll4YWMtS1d3SEZacXJhcktHczE4anRLaDNSa255MnVoVWxPcUlRYzBhQWxteTdObXloamJXbms4U2VPMUJ0VFhVNmh5LVZmaVNVczVyTUVGcHZJMS1ZVTRtTmZaV2Y5OHU1ZFJySDRaUFNQMkhtREd5SUNoVG5ZVWs0eXNkMVpMbHNyaC0yazllTTh6X05kekdRc0hLV21JZ3dxYS10VDJ6dzFsaUZhRDFnYllOTnBBNXEyR1BhZWxIeUFwbkM1X2FOZmV5NnROQlFwX1RzRFRkQ3VkOW1YN0lvaWR5QQ?oc=5" target="_blank">Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Multiple sclerosis: survival rates improve, but inequalities remain
healthcare-in-europe.comtech

Multiple sclerosis: survival rates improve, but inequalities remain

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOdXlKRXRiaTFocGZ6OW5ETHNfakRVMEMyOTk0N0c0UlpnUFh0YXYybmgxZjZOUHFadjBBdDhLdlFVazk5Vzc3bVhuaXdGdlo5WVFwaFc5SVA1VG1yR0lTaVY1RW9DQ2NvM1FsV2lkVl9zV0ZUUlRsYWJqNHlLWE9uVjVXSU1kT2lQcjdfVE5OQmpaRVM1NGZCZnNUa0dMZ2gtQUE?oc=5" target="_blank">Multiple sclerosis: survival rates improve, but inequalities remain</a>  <font color="#6f6f6f">healthcare-in-europe.com</font>

Read Full StoryMore like this
Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial
Cure Todaygeneral

Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPekpFdzkxdHVadERDcFVETlJNWUhiUkw2QzduYXY3TVh2RUx5U1h2QjA4X0pNVnhNZnVBWTNLOFNJVFVnZG42SnJyWmVpc3VJeTVVMjZPMU5JYmt4OWFiWnlQRlRRR2E2MlNUdXZkb3hsQ1k1X2ZRbE81bUFxSjJkVm8xYXNvSXNPeGgzbXZlTFpkdnJNcVY5SURfcUxvaUhrZlFpTHVZWFRKaTRz?oc=5" target="_blank">Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
MedPage Todaygeneral

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE4wc0dRdms0TllDNl96b3hRTXV0NkszcGJTOGd4TFVzWlJmSkRsdzRvWWsxaV9DRFR2TWhaenlreVYyZkpqaWF2WnpQUHNGTC1NWko5TlJVVUZjRzdUUnpHZk5CTU9wUHc?oc=5" target="_blank">Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
Early IVIG Use Associated With Reduced Infections and Improved Survival in Patients Receiving Talquetamab for Multiple Myeloma
Pharmacy Timesgeneral

Early IVIG Use Associated With Reduced Infections and Improved Survival in Patients Receiving Talquetamab for Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQM0FDakZySzNPY3JDRnotaVNXR2hRYUdha042NzBNLXhwcGVXWXBtQkVUM1h5S25Ec3hHdXRSUVFFVXFDMVA3aGcwMnBuajY2WVJ2MWNJckxaNmlVMTB4cWRPdTBEUVE0eldJTkR2ZG9SMnpNc3RRVVRIQkRfWmZES3Y4U2ZsUjNkQzJibFdSRmlmMzhxZFR4d2N6b2JPNy1nS0hsdFQtQUhKU3pNRzhhX19HcmFHNEJzODdkTDc2TzZvZS04YmcwVnBhQmFvOGlrbEQxcHYxeXFtZzhSSWw5dGIzN09sTk5qNWNtTHRXYW84U0U?oc=5" target="_blank">Early IVIG Use Associated With Reduced Infections and Improved Survival in Patients Receiving Talquetamab for Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Multiarterial CABG Improves Survival Regardless of Strategy
TCTMD.comgeneral

Multiarterial CABG Improves Survival Regardless of Strategy

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNZ3V3Tlo2MEhHbUw3b3M0N1FZR3FqRkpsQ0tnZFRERDVGdHlFT1pYLWRzeFdRWFVkN3pDaTJoRm9QSnJtYnVzeDRhYWhja1gtMEJHWWFnbjFaY0UzUTdwU0MyQm9pdkREWnJLcTRLaVJja3h0QkVQQ2RYb2ZuZEx1S2lNTGstMWN6RWdB?oc=5" target="_blank">Multiarterial CABG Improves Survival Regardless of Strategy</a>  <font color="#6f6f6f">TCTMD.com</font>

Read Full StoryMore like this
New Extramedullary Myeloma Treatment With Bispecific Antibodies Improves Survival Dramatically
Memorial Sloan Kettering Cancer Centergeneral

New Extramedullary Myeloma Treatment With Bispecific Antibodies Improves Survival Dramatically

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPZmxkdmZ0U2t6RnhMc1ZGZ1A4cUo4RnNsMzZIX2IyNS1UcHNZVi1PRExuZW1PX1FhY3FDaUpMLU8xUHhKT0Y0bzdWNlZzSGpNVkhzOVQ4Tmc5T0ZFZXBOOUppU1N3RFBHNVlBRXZEVXNkOEZGbWVXVUkxYXVCUjlqbURkRFJaeDVaYkhVeUlPbk5HdEJJaHF5a1lYSE13ek1GSGpvWl9iV3ViU1Zad2RiMVlMdkNzdnBXaG1ERGRB?oc=5" target="_blank">New Extramedullary Myeloma Treatment With Bispecific Antibodies Improves Survival Dramatically</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
Fierce Biotechgeneral

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQYzlUcWZuUFkzbDF4MlkxX0pNYzRWWFlrWmtrNGotM25UZC1PY1RyS0JjbTlyQzZzekF6X2R1UEVheDV3eHk1Z3puSnVtTkZ3UkgyTFJ1MWd0QjRIMEZpOFUtUzFOZzBQVXZad0E0Y0hXNlRZQlNXN1pHLTMtV0I3QXhTVlcyVWRiTEh2blpHaEpNeEVCVUxRbFZKV2RMRlJYRUp1dWJ0SnpYSTRMZzVz?oc=5" target="_blank">BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma
CancerNetworkgeneral

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPVTFhWGxLUFQxLVdyMXkyNzAtdkxjSHVWUTdScnpHSUtLdlFLUDJFcTlRRjdjaEI3TU9OSXZFaTViTmppTzN2YmFyTzAwTmR1VVdkemh4cEE1YjRPajNTMGxMc0R6ZXE5MkI1Rl9obS1CVDU1dEtZeUc4S2ZnN0hkVXBfeWs3Y2o3WUZCRFZjUU1zejdlUnlrU0tHVUwyYlJRZURiV2p3?oc=5" target="_blank">Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study | Blood Cancer Journal
Naturegeneral

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5BdWZTSUFLN0xZWkMxZVQ0b3dEMHcxR0JRbER2ajFlWWtkYUx5ZnhCaGhDOXl6T05FZFAyUTYxSWYxZi1sV3IwVnFtcUxhazhWS0xsU1RoVDhxRmRMd0xv?oc=5" target="_blank">Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities
AJMCtech

Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWmtPeFZidzRxN0x6ckpzVThpQk1wb3I1dXpZSm1xTUxSeXVEeGg4MVJNMkVWUXRnX0JTSF92dHFBanZ1WlNuMWczM3hXSElLWFR1MVNFZlNQQ01hMW9WbWRDNEtmTmRyVGxqMjh5eURFOTJ2VDlWVEVuVlNva2lfM3pmNnl4NFFCaGZtU2hsVzdFeTJ0MWpVNjFJQmlsVnVFVFd6SzZfLTZRUQ?oc=5" target="_blank">Survival Gains in Multiple Myeloma Highlight Progress and Persistent Disparities</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Carvykti Associated With Improved Survival in R/R Multiple Myeloma
Cure Todaygeneral

Carvykti Associated With Improved Survival in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOZExqd2ZOXzFoVTdmVkpwdV9aOTZhTlBqMTV0SXFzbWZNd2tGUnBidU5XRHNHMm44alFuWEFQb1FhLUstWllpZEh0Q0R0V3QwRG85WVdCeDJBUm9mU2wtWW0xRHBNT09HWGd1RmhzTlJZcy0xbmY0TzhDcDVPeGI5OWVxZEJWRjN0d0hyN3YzVFB0blRhS3dXdUtMMlU5QQ?oc=5" target="_blank">Carvykti Associated With Improved Survival in R/R Multiple Myeloma</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Multiple-treatment approach improves survival rates in aggressive prostate cancer, study finds
UCLA Healthgeneral

Multiple-treatment approach improves survival rates in aggressive prostate cancer, study finds

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNMXFHZjRTcG05d1VmT3lObi1aOHB0SEVqOXNKQkRoSjB0bnpqZGNGUS1TcjcwNldiZ21VdEU0WG0zN2JBU0lEcF9rVGQ5Y2NnakRkdG1Jek1HRVN3Ujh1Z3F6WWVDOU05TWotbkdaQU5IWTVOc1NCbllFbU9kcDVYY3NMOVh0aWp5WmRtZTNXNmFaczBsNmwxUTRjejdnY040dkQ2eFdkWGpucHBoS1dqb3k3aTh4WGh2VUlSNlhtd0F4aVEwN1A2WFRwZ28?oc=5" target="_blank">Multiple-treatment approach improves survival rates in aggressive prostate cancer, study finds</a>  <font color="#6f6f6f">UCLA Health</font>

Read Full StoryMore like this
Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction
Naturegeneral

Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0tajdtaFl5ekZaSTBCc3N2ODAyckNEdkhCYlA2OGl1cUZUUS1wcWlZYkZLWXdaT3hyZWFNVFp6UnN5VVZXbG5TLXh6STl0TEdMc1pxODRTTnNOejlfWHFB?oc=5" target="_blank">Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
Naturegeneral

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9oUjZaOUE3bUNVelZTX25pbWJoMEtrSjR0UWdqY3VTZlJmbnU4c0NQSlpFRVllYjZoNW9jcnRWVmJlMC1XeVo2Y3NyOVdkMHkxdFdKMGhIUEYzNk5yLVk4?oc=5" target="_blank">Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Improved survival in mult" — Live Google News Trends & Headlines